Increased expression of both CD55 and CD59 has been seen on MM cells during disease progression on daratumumab treatment, indicating that overexpression of complement inhibitors is likely tied to daratumumab resistance [35]. This evidence concerns the gene CD55 and Miyoshi myopathy.